https://www.biospace.com/summit-raises-200-million-also-expands-license-territories-for-ivonescimab
Summit Raises $200 Million; Also Expands License Territories for Ivonescimab - BioSpace
Jun 3, 2024 - Summit Therapeutics Inc. announced that the Company received and accepted an unsolicited offer from an institutional investor to purchase 22,222,222 shares of...
200 millionsummitraisesalso
https://www.insidermonkey.com/blog/revolution-medicines-summit-therapeutics-partner-on-ras-inhibitor-ivonescimab-combinations-for-solid-tumors-1563621/
Revolution Medicines, Summit Therapeutics Partner on RAS Inhibitor/Ivonescimab Combinations for...
Revolution Medicines Inc. (NASDAQ:RVMD) is one of the best high short interest stocks with huge upside potential. On June 30, Revolution Medicines and Summit...
ras inhibitorrevolutionmedicinessummittherapeutics
https://www.miragenews.com/ivonescimab-tops-pembrolizumab-in-phase-3-nsclc-1311803/
Ivonescimab Tops Pembrolizumab in Phase 3 NSCLC Study | Mirage News
Data from a Phase 3 study revealed that ivonescimab demonstrates a statistically significant and clinically meaningful improvement in progression-free
in phaseivonescimabtopspembrolizumab3